Carbimazole-d3

Carbimazole-d3 is deuterium labeled Carbimazole. Carbimazole is an orally active antithyroid agent which rapidly converts to Methimazole after absorption and prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of thyroxine. Carbimazole also displays anti-inflammatory and neuronal-protective activities, suggesting its application for hyperthyroidism and neurological research[1][2][3][4].

Product Specifications

UNSPSC

12352005

Target

Isotope-Labeled Compounds; p38 MAPK

Type

Isotope-Labeled Compounds

Related Pathways

MAPK/ERK Pathway; Others

Field of Research

Endocrinology; Neurological Disease

Smiles

S=C1N(C=CN1C(OCC)=O)C([2H])([2H])[2H]

Molecular Formula

C7H7D3N2O2S

Molecular Weight

189.25

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Nakashima, T. and A. Taurog, Rapid conversion of carbimazole to methimazole in serum; evidence for an enzymatic mechanism. Clin Endocrinol (Oxf), 1979. 10 (6) : p. 637-48.|[3]Lehane C, et al. Carbimazole is an inhibitor of protein synthesis and protects from neuronal hypoxic damage in vitro. J Pharmacol Exp Ther. 2013 Dec;347 (3) :781-93.|[4]H. Saeed, et al. Effects of Dose Level of Anti-thyroid Drug Carbimazole on Thermoregulation and Blood Constituents in Male Rabbits (Oryctolagus cuniculus) . Advances in Research, 2014, 2 (3), 129–144.